Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-393-1 | CAS number: 120-40-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From December 29, 1991 to April 16, 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 999
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- Deviations:
- not specified
- Principles of method if other than guideline:
- A 14-week toxicity study in mice was conducted to evaluate the cumulative toxic effects of repeated dermal exposure to the test substance.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Unknown impurities
- IUPAC Name:
- Unknown impurities
- Reference substance name:
- N,N-bis(2-hydroxyethyl)dodecanamide
- EC Number:
- 204-393-1
- EC Name:
- N,N-bis(2-hydroxyethyl)dodecanamide
- Cas Number:
- 120-40-1
- Molecular formula:
- C16H33NO3
- IUPAC Name:
- N,N-bis(2-hydroxyethyl)dodecanamide
- Reference substance name:
- 2,2'-iminodiethanol
- EC Number:
- 203-868-0
- EC Name:
- 2,2'-iminodiethanol
- Cas Number:
- 111-42-2
- Molecular formula:
- C4H11NO2
- IUPAC Name:
- 2,2’-iminodiethanol
- Test material form:
- other: Viscous light yellow liquid or a white to light yellow, waxy solid
impurity 1
Constituent 1
impurity 2
Test animals
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS:
- Source: Taconic Farms (Germantown, NY)
- Age at study initiation: Approximately 7 wk
- Housing: Housed individually in Polycarbonate cages
- Bedding: Sani-Chip® heat-treated hardwood chips (PJ Murphy Forest Products Corp., Montville, NJ), changed weekly
- Diet: NIH-07 open formula pelleted diet (Zeigler Brothers, Inc., Gardners, PA), available ad libitum (and changed weekly)
- Water: Tap water (Columbus municipal supply) via automatic watering system (Edstrom Industries, Inc., Waterford, WI), available ad libitum (cleaned every 2 wks)
- Acclimatization period: 14 d
- Cages: Polycarbonate (Lab Products, Inc., Maywood, NJ), changed weekly and rotated every 2 weeks
- Animal number per cage: 1 Bedding: Sani-Chip® heat-treated hardwood chips (PJ Murphy Forest Products Corp., Montville, NJ), changed weekly
- Cage Filters: Spun-bonded polyester Du Pont 2024 (Snow Filtration, Co., Cincinnati, OH), changed every 2 weeks
- Racks: Stainless steel drawer-type (Lab Products, Inc., Maywood, NJ), changed and rotated every 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature : 21.1-23.9°C
- Relative humidity : 42-57%
- Air changes : 10/hr
- Photoperiod : 12 h dark/12 h light
IN-LIFE DATES: From: 1992-01-13 To: 1992-04-14
Administration / exposure
- Type of coverage:
- open
- Vehicle:
- ethanol
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The dose formulations were prepared every 3 weeks by liquefying and stirring the test substance at approximately 70°C. A weighed amount of the test substance was mixed with approximately half the required 95% ethanol, and the mixture was sonicated until it appeared to be in solution. The solution was allowed to cool and was then diluted to volume with 95% ethanol to give the required concentrations.The test substance formulations were applied on shaved skin of the test animals.
-Stability studies of the 10 mg/mL dose formulation were performed by the study laboratory using HPLC. When stored in sealed glass containers and protected from light, the dose formulations were stable for at least 28 days between -20°C and room temperature. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Periodic analyses of the dose formulations of the test substance from the beginning, middle, and end of the studies were analyzed at the study laboratory using HPLC. All the samples from the formulations were within 10% of the target concentration.
-Stability studies of the 10 mg/mL dose formulation were performed by the study laboratory using HPLC. When stored in sealed glass containers and protected from light, the dose formulations were stable for at least 28 days between -20°C and room temperature. - Duration of treatment / exposure:
- 14 wks
- Frequency of treatment:
- 5 exposures/wk
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Dose / conc.:
- 400 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 per sex per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Method of animal grouping: Distributed randomly into groups of approximately equal initial mean body weights.
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily
BODY WEIGHT: Yes
- Time schedule for examinations: Weighed initially, weekly, and at the end of the studies
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
OTHER: Organs weighed were heart, right kidney, liver, lung, right testis, and thymus - Sacrifice and pathology:
- SACRIFICE: At the end of the 14 wk study, blood was collected from the retroorbital sinus of all core study mice for hematology and clinical chemistry analyses. Thereafter the test animals were anesthetised with a carbon dioxide/oxygen mixture.
GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes. Complete histopathology was performed on 0 and 400 mg/kg bw core study mice. In addition to gross lesions and tissue masses, the following tissues were examined: adrenal gland, bone and marrow, brain, clitoral gland, esophagus, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach (forestomach and glandular), testis (and epididymis and seminal vesicle), thymus, thyroid gland, trachea, urinary bladder, and uterus. In addition, the skin was examined in all mice. - Other examinations:
- Sperm motility and vaginal cytology: At the end of the studies, samples were collected for sperm motility or vaginal cytology from all mice in the 0, 100, 200, and 400 mg/kg bw groups for evaluations.
- The following sperm motility parameters was evaluated: spermatid heads per gram of testis, spermatid heads per testis, spermatid count, motility, and concentration in cauda epididymis. The left cauda, epididymis, and testis were weighed.
- Vaginal samples were collected for 12 consecutive days prior to the end of the studies for vaginal cytology evaluations. The length of the estrous cycle and the length of time spent in each stage of the cycle were evaluated. - Statistics:
- - Statistical analyses for possible dose-related effects on survival used Cox’s (1972) method for testing two groups for equality and Tarone’s (1975) life table test to identify dose-related trends.
- Analysis of neoplasm and non-neoplastic lesion incidences: The Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) was used to assess neoplasm and nonneoplastic lesion prevalence. Tests of significance included pair wise comparisons of each dosed group with controls and a test for an overall dose-related trend. Continuity-corrected tests were used in the analysis of lesion incidence, and reported P values are one sided. Values of P greater than 0.5 are presented as 1-P with the letter N added to indicate a lower incidence or negative trend in neoplasm occurrence relative to the control group (e.g., P=0.99 is presented as P=0.01N).
- Analysis of Continuous Variables: Organ and body weight data were analyzed using the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972).
- Hematology, clinical chemistry, spermatid, and epididymal spermatozoal data were analyzed using the nonparametric multiple comparison methods of Shirley (1977) and Dunn (1964). Prior to statistical analysis, extreme values identified by the outlier test of Dixon and Massey. Average severity values were analyzed for significance with the Mann-Whitney U test (Hollander and Wolfe, 1973). Treatment effects were investigated by applying a multivariate analysis of variance (Morrison, 1976) to the transformed data to test for simultaneous equality of measurements across dose levels.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Irritation of the skin at the site of application was noted in all males and females administered 400 or 800 mg/kg bw/day.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Increased absolute and/or relative kidney weights of in males at ≥100 mg/kg bw/day and in females at 800 mg/kg bw/day; increased liver weights in females at ≥200 mg/kg bw/day and reduced thymus weights in males at 400 and 800 mg/kg bw/day.
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Including epidermal and sebaceous gland hyperplasia, chronic inflammation, parakeratosis and ulcer in males and females at ≥200 mg/kg bw/day.
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- There were no significant differences in reproductive tissue evaluations or in estrous cycle characterization between dosed and vehicle control groups.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- (systemic effects)
- Effect level:
- 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- organ weights and organ / body weight ratios
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- (local effects)
- Effect level:
- ca. 100 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
For detailed tables kindly refer to the attached background materials section of the IUCLID.
Applicant's summary and conclusion
- Conclusions:
- Under the study conditions, the 14-weeks NOAELs for systemic and local effects in mice were 50 and 100 mg/kg bw/day, respectively.
- Executive summary:
A study was conducted to determine the repeated dose dermal toxicity of the test substance, C12 DEA, according to design based on OECD Guidance 411, in compliance with GLP. Groups of 10 male and 10 female mice were dermally exposed to 0, 50, 100, 200, 400 or 800 mg/kg bw/day in ethanol for 5 d/week during a period of 14 weeks. Mortality, clinical findings, body weight and histopathology were evaluated at specific time intervals. All animals survived until the end of the study and final mean body weights and body weight gains of dosed mice were generally similar to those of the vehicle control groups. Skin irritation at the site of application was noted in all males and females administered 400 or 800 mg/kg bw/day. The kidney weights of males receiving 100, 400, or 800 mg/kg bw/day and females receiving 800 mg/kg bw/day were significantly greater than those of the vehicle controls. Liver weights of females at 200 mg/kg bw/day or greater were significantly higher than those of vehicle controls. Increased incidences of non-neoplastic lesions of the skin at the site of application, including epidermal and sebaceous gland hyperplasia, chronic inflammation parakeratosis and ulcer, were observed in animals receiving 200 mg/kg bw/day or greater. Under the study conditions, the 14-week NOAELs for systemic and local effects in mice were 50 and 100 mg/kg bw/day, respectively (NTP, 1999).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.